help button home button The Oncologist http://theoncologist.alphamedpress.org/subscriptions/etoc.dtl
HOME HELP CONTACT US SUBSCRIPTIONS ARCHIVE SEARCH TABLE OF CONTENTS

This Article
Right arrow Full Text
Right arrow Full Text (PDF)
Right arrow eLetters: Submit a response to this article
Right arrow Alert me when this article is cited
Right arrow Alert me when eLetters are posted
Right arrow Alert me if a correction is posted
Right arrow Citation Map
Services
Right arrow E-mail this article link to a friend
Right arrow Similar articles in this journal
Right arrow Similar articles in PubMed
Right arrow Alert me to new issues of the journal
Right arrow Download to citation manager
Right arrow Reprints/Permissions
Citing Articles
Right arrow Citing Articles via HighWire
Right arrow Citing Articles via Google Scholar
Google Scholar
Right arrow Articles by Duhem, C.
Right arrow Articles by Dicato, M.
Right arrow Search for Related Content
PubMed
Right arrow PubMed Citation
Right arrow Articles by Duhem, C.
Right arrow Articles by Dicato, M.
The Oncologist, Vol. 1, No. 3, 151–158, June 1996
© 1996 AlphaMed Press

What does Multidrug Resistance (MDR) Expression Mean in the Clinic?

C. Duhem, F. Ries, M. Dicato

Hematology-Oncology, Centre Hospitalier, Luxembourg, Luxembourg

Correspondence: Professor Mario A. Dicato, M.D., Hematology-Oncology, Centre Hospitalier, L-1210, Luxembourg, Luxembourg. Telephone: 352-4411-2084; Fax: 352-441215.

For 15 years, an overflowing literature has been published about MDR-1 gene expression in tumor cell lines and in cancerous tissues at various stages of disease and treatment (chemotherapy-naive, during treatment and at relapse). However, the clinical significance of this particular feature, if it seemed obvious in the 1980s as a factor responsible for the development of chemoresistance, is currently reconsidered. MDR-1 gene expression seems to be, at least in some instances, a hallmark of tumor cell aggressiveness and of chemoresistance rather than its cause, the mechanisms of which are probably far more complex. The failure of MDR reversal trials might result from the misunderstood or overvalued role of MDR expression in cancer cells rather than from a lack of control of pharmacological parameters.

This review summarizes recent data and hypothesis about the expression of P-170 and its clinical significance in some important human tumor types, suggesting that it should rather be considered in the future as an adverse prognostic factor.

Key Words. MDR-1 gene • P-170 expression • Chemoresistance • Tumor aggressiveness




This article has been cited by other articles:


Home page
Br. J. Ophthalmol.Home page
S Krishnakumar, K Mallikarjuna, N Desai, A Muthialu, N Venkatesan, A Sundaram, V Khetan, and M P Shanmugam
Multidrug resistant proteins: P-glycoprotein and lung resistance protein expression in retinoblastoma
Br. J. Ophthalmol., December 1, 2004; 88(12): 1521 - 1526.
[Abstract] [Full Text] [PDF]




HOME HELP CONTACT US SUBSCRIPTIONS ARCHIVE SEARCH TABLE OF CONTENTS
THE ONCOLOGIST STEM CELLS CME ALPHAMED PRESS JOURNALS
http://theoncologist.alphamedpress.org/misc/eLetters.shtml

Copyright © 1996 by AlphaMed Press.